Navigation Links
Anaphore Appoints Paul A. Grayson President and CEO
Date:6/20/2011

LA JOLLA, Calif., June 20, 2011 /PRNewswire/ -- Anaphore Inc. today announced the appointment of Paul A. Grayson as president and CEO. A life sciences executive with an extensive track record of success in business development and financial transactions for emerging biopharmaceutical companies, Grayson joins Anaphore as it focuses its efforts on the establishment of collaborations with pharmaceutical companies for the discovery and development of novel Atrimer therapeutics. He replaces Katherine S. Bowdish, Ph.D., a co-founder of Anaphore, who will continue to serve the company as a consultant.

"I am proud of the collective accomplishments of the Anaphore team from inception to date including significantly advancing the core platform technology, programs, and forging a critical partnership," said Kathy Bowdish.  "I am confident of the team's ability to execute under Paul's direction as the company embarks in this next exciting stage in its evolution."

"The addition of Paul reflects Anaphore's movement into its next phase of development," said Russell G. Greig, Ph.D., the company's executive chairman. "His deal-making experience and leadership qualities will bring a new dimension to the company as we increase our efforts to unlock the value of our technology platform. We are grateful to Kathy for her success in building a top-notch scientific team and advancing the technology to this sophisticated stage."

Grayson commented, "I've had the opportunity to evaluate many leadership opportunities in the industry over the past months. Anaphore's Atrimer technology caught my attention and stood out as an innovative approach to tackling diseases that were out of reach because of limitations with today's protein drugs.  I am excited to join the company at its current stage and view this as an opportunity that is destined for success."

Grayson previously served as CEO of Fate Therapeutics, a San Diego-based, privately held biopharmaceutical company focused on the development of therapies that act through stem cell modulation.  Before this, he was managing director of Sanderling Ventures where he was a founding board member of multiple portfolio companies including: Calcimedica, Taligen Therapeutics (acquired by Alexion Pharmaceuticals), and Naviscan.  Prior to Sanderling, Grayson served as the founding Chairman and CEO of Senomyx Inc. and part of the founding management team of Aurora Biosciences (acquired by Vertex).

About Anaphore

Anaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Each of the three binding domains comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest.  Atrimer therapeutics potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies. Atrimer protein therapeutics are protected by intellectual property, including multiple patent families.

Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimer therapeutics against targets in a wide range of therapeutic areas, including rare diseases.

Anaphore recently formed a partnership with Mitsubishi Tanabe Pharma Corporation to discover and develop Atrimer drug candidates for the treatment of autoimmune disorders. Since its founding in 2008, Anaphore has raised $38 million in financing from top-tier biotechnology investors 5AM Ventures, Versant Ventures, Apposite Capital LLP, SR One, Merck Serono Ventures and Aravis SA.

For more information please visit www.anaphore.com.

Media Contact:
Ian Stone or David Schull
Russo Partners, LLC
619-528-2220
212-845-4271
ian.stone@russopartnersllc.com
david.schull@russopartnersllc.com


'/>"/>
SOURCE Anaphore
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
2. ID Analytics Appoints Chief Information Officer
3. ID Analytics Appoints Chief Information Officer
4. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
5. BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer
6. Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative
7. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
8. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
9. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
10. The Science Coalitions 10 questions for the presidential debate
11. Haag honored with Presidential Early Career Scientists Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
(Date:12/15/2016)... --  WaferGen Bio-systems, Inc. (NASDAQ: WGBS ... that on December 13, 2016, it received a letter ... Market LLC which acknowledged that, as of December 12, ... had been at $1.00 or greater for ten consecutive ... Rule 5550(a)(2) of the Nasdaq Stock Market. ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots , ... from around the world, was today awarded the "Best Science & Technology Social ... on merit and decided upon by a dedicated team of researchers and analysts. ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ), a ... live webcast of its Annual Meeting of Shareholders on Tuesday, January ... can be accessed from the BD corporate website at http://www.bd.com/investors/ ... ... BD is a global medical technology company that is ...
Breaking Biology Technology: